• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Boehringer Ingelheim acquires MabVax’s programme for solid tumours pharmaceutical-technology
    July 12, 2018
    Boehringer Ingelheim has entered an asset acquisition and licence agreement for US-based biotechnology firm MabVax Therapeutics’ programme designed to target a glycan that is commonly overexpressed on various solid tumours cancers.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service